secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0000950170-23-028621
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences annual meeting results and revised director comp: $45k retainer, $750k initial equity
--------------------------------------------------------------------------------

- All four director nominees elected; Ernst & Young ratified as auditor; say-on-pay approved with ~92% for.
- Board revised non-employee director compensation: annual cash retainer $45,000; additional committee chair retainers up to $25,000.
- Initial equity award ~$750,000 (2/3 options, 1/3 RSUs) with 3-year vesting; annual award ~$400,000 with 12-month or next meeting vesting.
- Compensation changes effective June 15, 2023, as detailed in Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/rcus-20230615.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer